KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Dynavax Technologies (DVAX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to 22.42%.

  • Dynavax Technologies' EBITDA Margin rose 99200.0% to 22.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.16%, marking a year-over-year increase of 73700.0%. This contributed to the annual value of 1.49% for FY2024, which is 144500.0% up from last year.
  • Per Dynavax Technologies' latest filing, its EBITDA Margin stood at 22.42% for Q3 2025, which was up 99200.0% from 15.12% recorded in Q2 2025.
  • In the past 5 years, Dynavax Technologies' EBITDA Margin registered a high of 50.0% during Q2 2022, and its lowest value of 64.46% during Q1 2023.
  • Over the past 5 years, Dynavax Technologies' median EBITDA Margin value was 14.84% (recorded in 2021), while the average stood at 8.57%.
  • In the last 5 years, Dynavax Technologies' EBITDA Margin skyrocketed by 8921600bps in 2021 and then plummeted by -914500bps in 2023.
  • Dynavax Technologies' EBITDA Margin (Quarter) stood at 41.38% in 2021, then dropped by -17bps to 34.22% in 2022, then crashed by -145bps to 15.27% in 2023, then skyrocketed by 85bps to 2.27% in 2024, then soared by 1090bps to 22.42% in 2025.
  • Its EBITDA Margin stands at 22.42% for Q3 2025, versus 15.12% for Q2 2025 and 34.67% for Q1 2025.